Live-attenuated Shigella vaccines.
Several live-attenuated Shigella vaccines, with well-defined mutations in specific genes, have shown great promise in eliciting significant immune responses when given orally to volunteers. These responses have been measured by evaluating antibody-secreting cells, serum antibody levels and fecal immunoglobulin A to bacterial lipopolysaccharide and to individual bacterial invasion plasmid antigens. In this review, data collected from volunteer trials with live Shigella vaccines from three different research groups are described. The attenuating features of the bacterial strains, as well as the immune response following the use of different dosing regimens, are also described. The responses obtained with each vaccine strain are compared with data obtained from challenge trials using wild-type Shigella strains. Although the exact correlates of protection have not been found, some consensus may be derived as to what may constitute a protective immune response. Future directions in the field of live Shigella vaccines are also discussed.
Venkatesan
Malabi M
MM
Division of Bacterial and Rickettsial Diseases, Walter Reed Army Institute of Research, 503 Robert Forney Drive, Room 3s12, Silver Spring, MD 20910, USA. malabi.venkatesan@na.amedd.army.mil
Ranallo
Ryan T
RT
D000293:Adolescent; D000328:Adult; D000818:Animals; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004405:Dysentery, Bacillary / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007113:Immunity, Innate; D007115:Immunization Schedule; D007223:Infant; D008887:Military Medicine; D012760:Shigella / Q000276:immunology* / Q000472:pathogenicity; D022281:Shigella Vaccines / Q000276:immunology*; D014481:United States; D014611:Vaccination / Q000639:trends; D014613:Vaccines, Attenuated / Q000276:immunology
D022281:Shigella Vaccines; D014613:Vaccines, Attenuated